Scientists have determined a drug that could treat people with genetic obesity by inhibiting their appetite and resulting in the decrease in weight of the person. About 2 to 6% of the people with obesity have mutations in one of their ‘appetite genes’. It gives a strong genetic predisposition for developing obesity, also known as monogenic obesity. In this case, feeling of hunger is overruling and of satiety is limited.
Such patients respond less to existing obesity treatments, therefore dieting and surgery can be a favourable option, but the long-term effect is poor. Researchers have discovered that such people with obesity can lose weight with the help of the medicine Liraglutide, which is a modified form of the appetite-inhibiting hormone GLP-1, naturally secreted from the intestine. The scientists stated that, “ Patients feel less hungry and lose six per cent of their body weight…
